The 212Pb-DOTAM-GRPR1 radiopharmaceutical is an α-particle-emitting radionuclide 212Pb, a metal chelator DOTAM, and a GRPR-targeted antagonist that is currently being studied in the metastatic uterine cervix cancer setting (NCT05283330) as well as in a variety of other cancer types. This evidence concerns the gene GRPR and cancer.